Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention.

Hui‐Hui Liu,Ye‐Xuan Cao,Jing‐Lu Jin,Qi Hua,Yan‐Fang Li,Yuan‐Lin Guo,Cheng‐Gang Zhu,Na‐Qiong Wu,Run‐Lin Gao,Jian‐Jun Li

DOI: https://doi.org/10.1161/jaha.120.018869

IF: 6.106

2021-01-30

Journal of the American Heart Association

Abstract:Background Previous studies have suggested a strong association of liver fibrosis scores (LFSs) with cardiovascular outcomes in patients with different cardiovascular diseases. Nonetheless, it is basically blank regarding the prognostic significance of LFSs in patients following percutaneous coronary intervention (PCI). This study sought to examine the potential role of LFSs in predicting long‐term outcomes in a large cohort of patients with stable coronary artery disease after elective PCI. Methods and Results In this multicenter, prospective study, we consecutively enrolled 4003 patients with stable coronary artery disease undergoing PCI. Eight currently available noninvasive LFSs were assessed for each subject. All patients were followed up for the occurrence of cardiovascular events including cardiovascular death, nonfatal myocardial infarction, and stroke. During an average follow‐up of 5.0±1.6 years, 315 (7.87%) major cardiovascular events were recorded. Subjects who developed cardiovascular events were more likely to have intermediate or high LFSs, including nonalcoholic fatty liver disease fibrosis score; fibrosis‐4 score; body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes mellitus score (BARD); and aspartate aminotransferase/alanine aminotransferase ratio. Furthermore, compared with subjects with low scores, those with intermediate plus high score levels had significantly increased risk of cardiovascular events (adjusted hazard ratios ranging 1.57–1.92). Moreover, the addition of non‐alcoholic fatty liver disease fibrosis score; fibrosis‐4 score; or body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes mellitus score into a model with established cardiovascular risk factors significantly improved the prediction ability. Conclusions High LFSs levels might be useful for predicting adverse prognosis in patients with stable coronary artery disease following PCI, suggesting the possibility of the application of LFSs in the risk stratification before elective PCI. Nonstandard Abbreviations and Acronyms APRI aspartate aminotransferase to platelet ratio index BARD body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes mellitus score CVE cardiovascular event FIB‐4 fibrosis‐4 score LFS liver fibrosis score NAFLD nonalcoholic fatty liver disease NFS nonalcoholic fatty liver disease fibrosis score Clinical Perspective What Is New? Currently, no data are available regarding the prognostic significance of liver fibrosis scores in patients following percutaneous coronary intervention. The present study first indicated the clinical impact of liver fibrosis scores on long‐term outcomes in a large cohort of patients with stable coronary artery disease following percutaneous coronary intervention. What Are the Clinical Implications? In patients with coronary artery disease following elective percutaneous coronary intervention, liver fibrosis scores might be novel tools for risk stratification and clinical strategy‐making. Further studies regarding the role of liver fibrosis scores in diverse cardiovascular diseases may be of clinical interest. Although the management of coronary artery disease (CAD) has developed and improved dramatically over the past 2 decades, CAD remains a leading cause of morbidity and mortality worldwide. 1 Percutaneous coronary intervention (PCI) has significantly reduced the rate of major adverse cardiovascular events (CVEs) in patients with CAD. 2 , 3 , 4 , 5 However, patients who are post‐PCI still constitute a high‐risk group for recurrent events and cardiovascular m -Abstract Truncated-

cardiac & cardiovascular systems